KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Debt to Equity (2017 - 2020)

Xenon Pharmaceuticals (XENE) has disclosed Debt to Equity for 4 consecutive years, with $0.08 as the latest value for Q1 2020.

  • Quarterly Debt to Equity fell 49.15% to $0.08 in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $0.08 through Mar 2020, down 49.15% year-over-year, with the annual reading at $0.17 for FY2019, N/A changed from the prior year.
  • Debt to Equity for Q1 2020 was $0.08 at Xenon Pharmaceuticals, down from $0.17 in the prior quarter.
  • The five-year high for Debt to Equity was $0.24 in Q1 2018, with the low at $0.08 in Q1 2020.
  • Average Debt to Equity over 4 years is $0.18, with a median of $0.18 recorded in 2019.
  • The sharpest move saw Debt to Equity soared 54.24% in 2019, then crashed 49.15% in 2020.
  • Over 4 years, Debt to Equity stood at $0.19 in 2017, then fell by 29.27% to $0.13 in 2018, then grew by 26.15% to $0.17 in 2019, then plummeted by 50.64% to $0.08 in 2020.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.08, $0.17, and $0.21 for Q1 2020, Q4 2019, and Q3 2019 respectively.